[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guizhou Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100628522","phase-iii-multicenter-randomized-controlled-clinical-study-of-three-dimensional-radiotherapy-for-primary-tumors-in-non-oligometastatic-stage-iv-non-small-cell-lung-cancer-100628522",false,"NCT07462728","Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Pathologically or cytologically confirmed stage IV NSCLC \\[9th edition, 2024\\];\n2. Non-oligometastatic disease (number of metastatic lesions \\> 5, regardless of the number of organs involved); patients with brain metastases must be conscious; the number of lung metastases must not affect lung function and allow for possible primary tumor radiotherapy;\n3. Treatment-naïve (no prior antitumor therapy); or disease control after 1-3 months of monotherapy with TKI, ALK inhibitor\u002FROS inhibitor; or disease control after 4-6 cycles of chemotherapy combined with immunotherapy;\n4. Age 18-80 years, ECOG 0-2 or KPS ≥70; no contraindications to radiotherapy, EGFR-TKI, ALK\u002FROS1 inhibitors, chemotherapy, or immunotherapy;\n5. No major organ dysfunction, or laboratory test results must meet the following criteria: Hematology , cardiac function, liver function , and renal function within normal ranges according to respective laboratory standards. Pulmonary function : FEV1 \\>50%, mild to moderate impairment of lung function.\n6. Signed informed consent before treatment (for radiotherapy, chemotherapy, immunotherapy, and targeted drug therapy);\n7. Good patient compliance with the treatment and follow-up.\n\nExclusion Criteria:\n\n1. Stage I-III NSCLC, oligometastasis (number of metastatic lesions ≤ 5), Stage IV NSCLC with malignant serous cavity effusion, or KPS ≤ 60;\n2. Patients with extensive liver metastases or lung metastases that have severely impaired liver or lung function;\n3. Patients with uncontrolled hypertension, diabetes, unstable angina, history of myocardial infarction, symptomatic congestive heart failure within the past 12 months, or uncontrolled arrhythmia; clinically diagnosed valvular heart disease; active bacterial, fungal, or viral infections; mental disorders; severe pulmonary dysfunction;\n4. Pregnant or lactating patients;\n5. Patients with a history of other active malignant tumors prior to enrollment, except for non-small cell lung cancer; excluding non-melanoma skin basal cell carcinoma, cervical carcinoma in situ, and cured early-stage prostate cancer;\n6. Patients with allergic constitution or known\u002Fsuspected allergy to any investigational drugs without alternative medications;\n7. Patients with poor compliance; Patients deemed unsuitable for participation in this trial by the investigator.","ALL","18 Years","80 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","For patients with non-small cell lung cancer and more than five metastatic lesions (non-oligometastatic disease), does radical treatment of the primary lung lesion, in addition to pharmacotherapy, also provide benefits in terms of progression-free survival (PFS) and local control? Currently, there is limited clinical research on combining pharmacotherapy with radiotherapy for the primary lesion in non-oligometastatic patients. Therefore, this study aims to investigate whether radical radiotherapy targeting the primary lung lesion, in addition to pharmacotherapy, can improve local control and survival in non-oligometastatic patients, and whether the associated toxicities are acceptable.",[26,27],"Non Small Cell Lung Cancer Metastatic","Radiotherapy",[29,30,31],"non-oligometastatic NSCLC","radical radiotherapy of the primary lung lesion","pharmacotherapy with radiotherapy for the primary lesion","NOT_YET_RECRUITING","2026-03-08",{"date":35,"type":36},"2026-03-10","ACTUAL",{"date":38,"type":20},"2026-03-30",{"date":40,"type":20},"2027-12-30",{"name":42,"class":43},"Guizhou Medical University","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100450795","radiotherapy-or-observation-of-liver-metastases-in-small-cell-lung-cancer-100450795","NCT05150145","Radiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer","A Prospective Phase II Randomized Clinical Study of Radiotherapy or Observation of Liver Metastases for Small Cell Lung Cancer.","Inclusion Criteria\n\n1. Informed consent (radiation, medication) before treatment;\n2. Age 18 to 70 years old,regardless of gender;\n3. Initial SCLC confirmed by histopathological or cytological examination;\n4. Metastatic lesions in the distant area: included liver metastasis；\n5. Physical status score ECOG: 0 to 2；\n6. The expected survival time is more than 3 months;\n7. Bone marrow function:hemoglobin(HGB)\\>90g\u002FL,platelet(PLT)\\>100×109\u002FL,neutrophil cell(WBC)\\>1.5×109\u002FL(\\*normal value);\n8. Liver function:alanine aminotransferase(ALT) and aspertate aminotransferase(AST)\\\u003C1.5 times of the upper limit of normal(ULN);Total bilirubin \\\u003C1.5ULN;\n9. Renal function:Serum creatinine was lower than 1.5ULN,and the endogenous creatinine clearance rate(Ccr) is higher than 55mL\u002Fmin;\n10. Initial treatment (previously did not receive any thoracic radiotherapy or surgery).\n\nExclusion Criteria:\n\n1. patients with history of mental illness;\n2. patients combined with other malignancies;\n3. Active period of disease caused by bacteria, fungi or viruses; and these severe infection requiring intravenous antibiotics,antifungal or antiviral therapy;\n4. Patients with serious cardiovascular disease ,including uncontrolled hypertension, unstable angina,history of myocardial infarction within the past 12 months,and severe arrhythmias.\n5. Patients with poorly controlled diabetes who are judged to be unfit for chemotherapy by doctors.\n6. History of hepatitis and cirrhosisi ;\n7. pregnant, lactating patients;\n8. Patients with poor compliance；\n9. Researchers believe that it is not appropriate to participate in this test.","70 Years",{"count":53,"type":20},66,[23],"The aim of this randomized study is to investigate local tumor control,survival outcomes and complications on patients of liver metastasis in small cell lung cancer.",[57],"Radiotherapy; Complications",[59],"Radiotherapy;liver metastases;Small cell lung cancer;","RECRUITING","2025-06-22",{"date":63,"type":36},"2025-06-26",{"date":65,"type":36},"2021-04-30",{"date":67,"type":20},"2026-03-01",{"name":42,"class":43},1,""]